Naturmega

Отрасль

Корма, Пищевые ингредиенты

Темы

Микроводоросли (спирулина, хлорелла, эвглена), Корма и кормовые добавки

Роль

Производитель — “…izes in the development and manufacturing of omega-3 ingredients for the nutraceutical, pharmaceutical, and an…”

Почему это биоэкономика

Naturmega производит ингредиенты омега-3, в том числе из водорослей, с глубокой очисткой для нутрицевтики и питания.

Как найдена

TASA – Tecnológica de Alimentos; [Asia] Algaetech International; [Asia] Algal Bio; [Asia] CABIO 嘉必优 (SSE 688089)

Пока не указана поставщиком в решениях с доказательствами.

• 2026-07-01 Naturmega & BIOS Foundation Advance New Clinical Study on Phospholipid Omega-3 in Colombia - NATURMEGA
  Naturmega, in collaboration with BIOS Foundation, is advancing a clinical study in Colombia on a next-generation phospholipid omega-3 (Ruby-O®) to assess its cardiovascular benefits in mixed dyslipidemia, building on recent evidence of superior Omega-3 Index …
• 2025-10-22 Naturmega obtiene puesto #17 entre las empresas más innovadoras de Colombia 2025 - BASC
  Naturmega S.A. (C.I. NATURMEGA) is recognized as one of Colombia’s 30 most innovative companies in 2025, ranking #17 nationally and #6 in the “Héroe” archetype for purpose-driven, socially impactful innovation, supported by BASC Barranquilla and industry …
• 2025-09-11 Naturmega Announces Official Launch of State-of-the-Art Supercritical Fluid Fractionation Facility, First of Its Kind in South America - NATURMEGA
  Naturmega announces the launch of South America’s first Supercritical Fluid Fractionation Facility for omega-3s, highlighting its leadership in cleaner, more sustainable, and ultra-purified EPA/DHA production (up to 80%). The company, with 30+ years in omega-3 …
• 2026-05-25 Naturmega Advances Ruby-O® Clinical Program with Newly Registered Trial - NATURMEGA
  Naturmega is advancing its Ruby-O® phospholipid omega-3 platform with a registered double-blind clinical trial in adults with mixed dyslipidemia to evaluate delivery, metabolic markers, and cardiovascular outcomes over 24 weeks, signaling a broader 2026 …
• 2026-09-04 Naturmega’s SUPRIAX2 solution to make its North American debut at SupplySide Global 2026
  Naturmega is positioning itself as a next‑generation lipid science company, launching its SUPRIAX2 bonded-phospholipid omega‑3 (Ruby-O) solution—first in its BeyondKrill portfolio—aimed at higher potency, neutral sensory profiles, and flexible formulations …
• 2026-01-20 Naturmega® Announces Peer-Reviewed Clinical Results for Ruby-O® Balance, Demonstrating Stronger Triglyceride Responder Outcomes with a Lower Omega-3 Dose - NATURMEGA
  Naturmega reports peer-reviewed clinical results for Ruby-O® Balance showing superior triglyceride reduction and 34% greater omega-3 efficiency at a lower dose, validating its Bonded Phospholipid Omega-3 platform (BPL-O3) for more efficient omega-3 delivery …

Владельцы и инвесторы 1

Похожие компании

SPES S.A. · TASA · Solutex Corp · Atacama Bio Natural Products S.A. · NaturaExtracta · Concepta Ingredients · Laboratorio ENA · PROVEFARMA S.A.